EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS IN THE TREATMENT OF HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS CO-INFECTION
DOI:
https://doi.org/10.54620/cadesp.v17i1.1346Keywords:
Drug Therapy, Treatment Outcome, Hepatitis C, Chronic, HIV Infections, CoinfectionAbstract
To analyze the outcome of treatments for chronic hepatitis C with direct-acting antivirals in patients coinfected with the human immunodeficiency virus, both in terms of effectiveness and therapeutic safety. Cross-sectional, single-center study, with a quantitative approach, conducted in a public outpatient clinic of reference in viral hepatitis in Ceará. Demographic and clinical information was collected from medical records of patients with hepatitis C virus and human immunodeficiency virus co-infection treated between October 2015 and February 2022. Most patients were male, aged between 40 and 60 years, infected with hepatitis C virus genotype 1 and treated with the antivirals sofosbuvir and daclatasvir. Only 7.9% had therapeutic failure, with 66.7% of these infected by genotype 3. Most (35; 92.1%) patients had sustained virological response. Mild adverse reactions have been documented in — the smallest proportion of subjects. Genotype 3 appears to be a challenge in the therapeutic regimen of the population with hepatitis C virus and human immunodeficiency virus co-infection.
Downloads
References
Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T et al. ICTV Virus Taxonomy Profile: Flaviviridae. J Gen Virol. 2017 Jan;98(1):2-3. DOI: 10.1099/jgv.0.000672. DOI: https://doi.org/10.1099/jgv.0.000672
Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM et al. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. J Infect Dis. 2018 Oct 20;218(11):1722-1729. DOI: 10.1093/infdis/jiy401. DOI: https://doi.org/10.1093/infdis/jiy401
Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol. 2016 Oct;65(1 Suppl):S2-S21. DOI: 10.1016/j.jhep.2016.07.035. DOI: https://doi.org/10.1016/j.jhep.2016.07.035
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016 Sep 14;22(34):7824-40. DOI: 10.3748/wjg.v22.i34.7824. DOI: https://doi.org/10.3748/wjg.v22.i34.7824
WHO | World Health Organization [Internet]. Global hepatitis report, 2017; [cited Jan 2022]. Available from: https://www.who.int/publications/i/item/9789241565455.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/AIDS e das Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para Hepatite C e coinfecções. Brasília: Ministério da Saúde; 2017. 138 p.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Boletim Epidemiológico - Hepatites Virais 2021. Brasília: Ministério da Saúde; 2021. 80 p.
Távora LGF, Hyppolito EB, Cruz JNM, Portela NMB, Pereira SM, Veras CM. Hepatitis B, C and HIV co-infections seroprevalence in a Northeast Brazilian center. Arq Gastroenterol. 2013 Oct/Dez; 50(4). DOI: 10.1590/S0004-28032013000400007. DOI: https://doi.org/10.1590/S0004-28032013000400007
Noubissi EC, Katte JC, Sobngwi E. Diabetes and HIV. Curr Diab Rep. 2018 Oct 8;18(11):125. DOI: 10.1007/s11892-018-1076-3. DOI: https://doi.org/10.1007/s11892-018-1076-3
Wyatt CM. Kidney Disease and HIV Infection. Top Antivir Med. 2017 Feb/Mar;25(1):13-16.
Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K et al. HIV/HCV coinfection and the risk of cardiovascular disease: A meta-analysis. J Viral Hepat. 2017 Nov;24(11):998-1004. DOI: 10.1111/jvh.12725. DOI: https://doi.org/10.1111/jvh.12725
Bedimo R, Maalouf NM, Lo Re V 3rd. Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture. Curr Opin HIV AIDS. 2016 May;11(3):285-93. DOI: 10.1097/COH.0000000000000259. DOI: https://doi.org/10.1097/COH.0000000000000259
Zahr NM. The Aging Brain With HIV Infection: Effects of Alcoholism or Hepatitis C Comorbidity. Front Aging Neurosci. 2018 Mar 22;10:56. DOI: 10.3389/fnagi.2018.00056. DOI: https://doi.org/10.3389/fnagi.2018.00056
Ingiliz P, Rockstroh JK. Natural history of liver disease and effect of hepatitis C virus on HIV disease progression. Curr Opin HIV AIDS. 2015 Sep;10(5):303-8. DOI: 10.1097/COH.0000000000000187. DOI: https://doi.org/10.1097/COH.0000000000000187
AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES;
INFECTIOUS DISEASES SOCIETY OF AMERICA [internet]. Recommendations for testing, managing, and treating hepatitis C; [cited Feb 2022]. Available from: http://www.hcvguidelines.org.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol. 2020 Nov;73(5):1170-1218. DOI: 10.1016/j.jhep.2020.08.018. DOI: https://doi.org/10.1016/j.jhep.2020.08.018
Mayberry J, Lee WM. The Revolution in Treatment of Hepatitis C. Med Clin North Am. 2019 Jan;103(1):43-55. DOI: 10.1016/j.mcna.2018.08.007. DOI: https://doi.org/10.1016/j.mcna.2018.08.007
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16;370(3):211-21. doi: 10.1056/NEJMoa1306218. Erratum in: N Engl J Med. 2014 Apr 10;370(15):1469. DOI: https://doi.org/10.1056/NEJMx140011
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Doenças Sexualmente Transmissíveis, AIDS e Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para Hepatite C e coinfecções. Brasília: Ministério da Saúde; 2015. 98 p.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Nota Informativa nº 13/2019-COVIG/CGVP/.DIAHV/SVS/MS. Atualização da Nota Informativa nº 13/2019, que dispõe acerca dos medicamentos disponibilizados para o tratamento da Hepatite C no SUS, considerando o critério de custo-minimização. Brasília: Ministério da Saúde; 2019. 3 p.
Machado SM, Vigani AG, Leite AG, Diaz ACM, Ferreira PRA, Carnaúba-Júnior D et al. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study. Medicine (Baltimore). 2020 Jul 24;99(30):e21270. DOI: 10.1097/MD.0000000000021270. DOI: https://doi.org/10.1097/MD.0000000000021270
Silva CM, Peder LD, Thomazella MV, Teixeira JJV, Bertolini DA. Profile of HCV genotypes and HIV-subtypes among HIV-coinfected patients in southern Brazil. Arq. Gastroenterol. Oct-Dec 2019;56(04). DOI: 10.1590/S0004-2803.201900000-68. DOI: https://doi.org/10.1590/s0004-2803.201900000-68
Nutini MFR, Hunter J, Giron L, Pires AFNPC, Kohiyama IM, Camargo M et al. HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: A survey representative of an entire country. PLoS One. 2020 Jan 6;15(1):e0227082. DOI: 10.1371/journal.pone.0227082. DOI: https://doi.org/10.1371/journal.pone.0227082
Wolff FH, Fuchs SC, Barcellos NN, de Alencastro PR, Ikeda ML, Brandão AB et al. Co-infection by hepatitis C virus in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates. PLoS One. 2010 May 5;5(5):e10494. DOI: 10.1371/journal.pone.0010494. DOI: https://doi.org/10.1371/journal.pone.0010494
Mendes-Correa MC, Cavalheiro NP, Mello C, Barone AA, Gianini RJ. Genotypic distribution of hepatitis C among hepatitis C and HIV co-infected patients in Brazil. Int J STD AIDS. 2008 Sep;19(9):595-9. DOI: 10.1258/ijsa.2007.007183. DOI: https://doi.org/10.1258/ijsa.2007.007183
Freitas SZ, Teles SA, Lorenzo PC, Puga MA, Tanaka TS, Thomaz DY, Martins RM, Druzian AF, Lindenberg AS, Torres MS, Pereira SA, Villar LM, Lampe E, Motta-Castro AR. HIV and HCV coinfection: prevalence, associated factors and genotype characterization in the Midwest Region of Brazil. Rev Inst Med Trop Sao Paulo. 2014 Nov-Dec;56(6):517-24. DOI: 10.1590/s0036-46652014000600011. DOI: https://doi.org/10.1590/S0036-46652014000600011
Secretaria da Saúde do Estado do Ceará. Coordenadoria de Vigilância Epidemiológica e Prevenção em Saúde. Boletim epidemiológico - HIV/AIDS. N. 2. Fortaleza: Secretaria da Saúde do Estado do Ceará; 2021. 20p.
Filho ECC, Piedade J, Castro R, Luz PM, Fernandes F, Grinsztejn B et al. Effectiveness of direct-acting agents for chronic hepatitis C treatment in South America: A systematic review and meta-analysis. J Viral Hepat. 2020 Dec;27(12):1396-1407. DOI: 10.1111/jvh.13364. DOI: https://doi.org/10.1111/jvh.13364
Schlabe S, Rockstroh JK. Advances in the treatment of HIV/HCV coinfection in adults. Expert Opin Pharmacother. 2018 Jan;19(1):49-64. DOI: 10.1080/14656566.2017.1419185.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Ofício Circular n Nº 6/2022/CGAHV/.DCCI/SVS/MS. Revoga e substitui as orientações do Ofício Circular nº 3/2022/CGAHV/.DCCI/SVS/MS e da Nota Informativa nº 13/2019-COVIG/CGVP/.DIAHV/SVS/MS, e estabelece os esquemas terapêuticos disponíveis para o tratamento da Hepatite C, no âmbito do SUS. Brasília: Ministério da Saúde; 2019. 5 p.
Poordad F, Shiffman ML, Ghesquiere W, Wong A, Huhn GD, Wong F et al. Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C). Antivir Ther. 2019;24(1):35-44. DOI: 10.3851/IMP3278. DOI: https://doi.org/10.3851/IMP3278
Dalgard O, Weiland O, Noraberg G, Karlsen L, Heggelund L, Färkkilâ M. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. PLoS One. 2017 Jul 13;12(7):e0179764. DOI: 10.1371/journal.pone.0179764. DOI: https://doi.org/10.1371/journal.pone.0179764
Sulkowski MS. Interferon-containing and interferon-free HCV therapy for HIV-infected patients. Semin Liver Dis. 2014 Feb;34(1):72-8. DOI: 10.1055/s-0034-1371012. DOI: https://doi.org/10.1055/s-0034-1371012
Schlabe S, Rockstroh JK. Advances in the treatment of HIV/HCV coinfection in adults. Expert Opin Pharmacother. 2018 Jan;19(1):49-64. DOI: 10.1080/14656566.2017.1419185. DOI: https://doi.org/10.1080/14656566.2017.1419185
Downloads
Published
How to Cite
Conference Proceedings Volume
Section
Categories
License
Copyright (c) 2023 Cadernos ESP
This work is licensed under a Creative Commons Attribution 4.0 International License.
Accepted 2023-09-11
Published 2023-12-26
